Italian Medicines Agency Agenzia Italiana del Farmaco

Expansion of prescription criteria for antiviral medicines - Expansion of prescription criteria for antiviral medicines

Asset Publisher

Asset Publisher

Expansion of prescription criteria for antiviral medicines

Following the decision of the Scientific Technical Committee (CTS) that standardised the prescription criteria for antiviral medicines (remdesivir, nirmatrelvir/ritonavir and molnupiravir) and anti-SARS-CoV-2 monoclonal antibodies, as they are directed to the same population group represented by individuals with mild/moderate COVID-19 disease and high risk of developing severe disease, the Agency makes available the new therapeutic plan for the prescription of Paxlovid (in 'Related documents').

The computerized prescribing systems (web-based TP for the prescription of nirmatrelvir/ritonavir by the general practitioner and AIFA monitoring registers for the prescription of remdesivir, molnupiravir and monoclonal antibodies by the centres identified by the Regions) have been implemented with the appropriate modifications and are operational as of 24 May 2022.


Published on: 24 May 2022

Asset Publisher

Asset Publisher

Site Map

Share

Galleria

Cookie Bar

cookie management module

Descrizione cookieBar

Questo sito utilizza cookie tecnici e analytics, necessari al suo funzionamento, per i quali non è richiesto il consenso. Per alcuni servizi aggiuntivi, le terze parti fornitrici, dettagliatamente sotto individuate, possono utilizzare cookies tecnici, analytics e di profilazione. Per saperne di più consulta la PRIVACY POLICY. Per proseguire nella navigazione devi effettuare la scelta sui cookie di terze parti dei quali eventualmente accetti l’utilizzo. Chiudendo il banner attraverso la X in alto a destra rifiuti tutti i cookie di terze parti. Puoi rivedere e modificare le tue scelte in qualsiasi momento attraverso il link "Gestione cookie" presente nel footer.

Social networks
go to beginning of content